Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis
- Author
- BAERT, F1 ; VANDE CASTEELE, N2 ; TOPS, S2 ; NOMAN, M1 ; VAN ASSCHE, G1 ; RUTGEERTS, P1 ; GILS, A2 ; VERMEIRE, S1 ; FERRANTE, M1
[1] Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
[2] Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium - Source
Alimentary pharmacology & therapeutics. 2014, Vol 40, Num 11-12, pp 1324-1332, 9 p ; ref : 26 ref
- ISSN
- 0269-2813
- Scientific domain
- Pharmacology drugs
- Publisher
- Blackwell, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Adalimumab Antipsoriasique Facteur prédictif Immunodépresseur Immunomodulateur Infliximab Liquide biologique Médicament Précoce Rectocolite ulcérohémorragique Sérum Anti-TNF-alpha Anticorps monoclonal Anticytokine Cytokine Facteur nécrose tumorale α Maladie inflammatoire Pathologie de l'appareil digestif Pathologie de l'intestin
- Keyword (en)
- Adalimumab Antipsoriatic agent Predictive factor Immunosuppressive agent Immunomodulator Infliximab Biological fluid Drug Early Ulcerative colitis Serum Anti-Tumor Necrosis Factor-alpha Monoclonal antibody Anticytokine Cytokine Tumor necrosis factor α Inflammatory disease Digestive diseases Intestinal disease
- Keyword (es)
- Adalimumab Antipsoriásico Factor predictivo Inmunodepresor Inmunomodulador Infliximab Líquido biológico Medicamento Precoz Rectocolitis ulcerohemorrágica Suero Anti-TNF alfa Anticuerpo monoclonal Anticitoquina Citoquina Factor necrosis tumoral α Enfermedad inflamatoria Aparato digestivo patología Intestino patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B13 Gastroenterology. Liver. Pancreas. Abdomen / 002B13B Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / 002B13B03 Other diseases. Semiology
- Discipline
- Gastroenterology. Liver. Pancreas. Abdomen
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28912166
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1111/apt.12968 
https://dx.doi.org/10.1111/apt.12968
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/apt.12968\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:5:\"11-12\";s:8:\"\u0000*\u0000spage\";s:4:\"1324\";s:8:\"\u0000*\u0000epage\";s:4:\"1332\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BAERT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:17:\"VANDE CASTEELE, N\";i:1;s:7:\"TOPS, S\";i:2;s:8:\"NOMAN, M\";i:3;s:13:\"VAN ASSCHE, G\";i:4;s:12:\"RUTGEERTS, P\";i:5;s:7:\"GILS, A\";i:6;s:11:\"VERMEIRE, S\";i:7;s:11:\"FERRANTE, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/apt.12968\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:5:\"11-12\";s:8:\"\u0000*\u0000spage\";s:4:\"1324\";s:8:\"\u0000*\u0000epage\";s:4:\"1332\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BAERT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:17:\"VANDE CASTEELE, N\";i:1;s:7:\"TOPS, S\";i:2;s:8:\"NOMAN, M\";i:3;s:13:\"VAN ASSCHE, G\";i:4;s:12:\"RUTGEERTS, P\";i:5;s:7:\"GILS, A\";i:6;s:11:\"VERMEIRE, S\";i:7;s:11:\"FERRANTE, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/apt.12968\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/apt.12968\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:5:\"11-12\";s:8:\"\u0000*\u0000spage\";s:4:\"1324\";s:8:\"\u0000*\u0000epage\";s:4:\"1332\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BAERT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:17:\"VANDE CASTEELE, N\";i:1;s:7:\"TOPS, S\";i:2;s:8:\"NOMAN, M\";i:3;s:13:\"VAN ASSCHE, G\";i:4;s:12:\"RUTGEERTS, P\";i:5;s:7:\"GILS, A\";i:6;s:11:\"VERMEIRE, S\";i:7;s:11:\"FERRANTE, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/apt.12968\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:5:\"11-12\";s:8:\"\u0000*\u0000spage\";s:4:\"1324\";s:8:\"\u0000*\u0000epage\";s:4:\"1332\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BAERT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:17:\"VANDE CASTEELE, N\";i:1;s:7:\"TOPS, S\";i:2;s:8:\"NOMAN, M\";i:3;s:13:\"VAN ASSCHE, G\";i:4;s:12:\"RUTGEERTS, P\";i:5;s:7:\"GILS, A\";i:6;s:11:\"VERMEIRE, S\";i:7;s:11:\"FERRANTE, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:17:\"10.1111\/apt.12968\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Alimentary pharmacology & therapeutics\";s:9:\"\u0000*\u0000stitle\";s:24:\"Aliment. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"40\";s:8:\"\u0000*\u0000issue\";s:5:\"11-12\";s:8:\"\u0000*\u0000spage\";s:4:\"1324\";s:8:\"\u0000*\u0000epage\";s:4:\"1332\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0269-2813\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"BAERT\";s:10:\"\u0000*\u0000aufirst\";s:1:\"F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:17:\"VANDE CASTEELE, N\";i:1;s:7:\"TOPS, S\";i:2;s:8:\"NOMAN, M\";i:3;s:13:\"VAN ASSCHE, G\";i:4;s:12:\"RUTGEERTS, P\";i:5;s:7:\"GILS, A\";i:6;s:11:\"VERMEIRE, S\";i:7;s:11:\"FERRANTE, M\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:116:\"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:9:\"Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
